Earnings Releases·Nov 2, 2026, 4:17 PM ET

Celanese Corporation — Third Quarter 2026 Earnings Summary

Net sales reached $2.6 billion (up 6% YoY, down 7% QoQ), while U.S. GAAP diluted EPS from continuing operations recovered to $0.68 from a $12.39 loss in the prior year; adjusted diluted EPS rose to $1.65 from $1.34.
Full-year 2026 guidance was raised to adjusted EPS of $6.00–$6.25 and free cash flow of $750–$800 million, with management targeting a net debt-to-operating EBITDA ratio of approximately 4.7x.
Strategic capital allocation includes a definitive agreement to sell an additional 19% stake in the Nutrinova joint venture to Mitsui & Co. for ~$152 million, expected to close in Q4 2026, alongside a long-term divestiture objective of $1 billion by end-2027.
Business performance was driven by Acetyl Chain sales growth of 14% YoY and Engineered Materials gains in medical and electronics applications, supported by new strategic partnerships and facility optimizations in Europe and Asia.